- Selected for official ‘Company Presentation’ session at BIO USA…Anticipated to strengthen partnership and investment attraction opportunities
- 바카라 토토 사이트-128 (macrophage engager) and ‘aPD-L1xVEGF-inclusive trispecific antibody’ unveiled as next-generation growth drivers
[by Lee, Young Sung] GI Innovation has introduced its trispecific antibody platform, marking its first public introduction of a technology designed to exceed the capabilities of the existing 'aPD-(L)1xVEGF' dual antibodies currently in development in the global market. Additionally, the company presented 'GI-128,' a macrophage-based candidate recognized as a next-generation therapeutic target in the field of immunotherapy.
바카라 토토 사이트 Innovation announced on June 18 that it has been selected to participate in the 'Company Presentation' session, an official program of the 2025 BIO International Convention (BIO USA), the world's largest biotechnology event, taking place in Boston, USA, from June 16 to 19 (local time).
During its presentation on the 17th (local time), 바카라 토토 사이트 Innovation showcased its new pipeline and global business strategy, positioning them as next-generation growth drivers. The presentation garnered great interest from investors and global pharmaceutical companies.
In particular, 바카라 토토 사이트 Innovation underscored its mid- to long-term global vision and technolo바카라 토토 사이트cal competitiveness by introducing '바카라 토토 사이트-128,' a macrophage-based candidate that has recently gained attention as a next-generation immunotherapy target, along with a trispecific antibody pipeline that exceeds the capabilities of the aPD-(L)1/VEGF dual antibody, which is rapidly gaining traction in the global market.
The aPD-(L)1/VEGF dual antibody is one of the most notable trends in the immunotherapy field, prompting a series of large-scale deals among major global pharmaceutical companies. Recently, the multinational pharmaceutical company Bristol Myers Squibb (BMS) entered into a mega-deal with BioNTech for the introduction of an aPD-L1/VEGF dual antibody, with an upfront payment of around KRW 2 trillion (approximately USD 1.4 billion) and a total contract value of approximately KRW 15.3 trillion. Similarly, MSD (Merck & Co., USA) signed a deal with China’s LaNova Medicines in 2024, involving a contract amount of about KRW 900 billion and a total deal value of KRW 4.5 trillion.
The newly introduced pipeline features a trispecific antibody structure that integrates 바카라 토토 사이트 Innovation’s proprietary aPD-L1 antibody with a VEGF antibody and a macrophage engager. According to the company, this construct is regarded as having a differentiated mechanism of action, as it addresses the limitations of dual antibodies while enhancing intratumoral immunity activation.
“BIO USA is a stage closely watched by global investors and major pharmaceutical companies, making it an excellent opportunity to effectively showcase the competitiveness of our new pipeline and global expansion strategy,” said Jang Myoung-ho, CEO of 바카라 토토 사이트 Innovation. “With this presentation, we will actively pursue various global partnership opportunities, including technology licensing, co-development, and investment attraction,” he added.